Alveolar Soft Part Sarcoma (ASPS) Cell Models for Research

Alveolar Soft Part Sarcoma (ASPS) is an ultra-rare soft tissue sarcoma, accounting for less than 1% of all soft tissue sarcomas. The global incidence is estimated at 0.1–0.2 cases per million person-years (WHO Classification of Tumours, 5th edition, 2020). ASPS predominantly affects adolescents and young adults (median age 20–30 years), with a slight female predominance. The 5-year survival rate for localized disease is approximately 60–70%, but for metastatic disease, it drops to less than 20% (NCI SEER data, 2023). The most common metastatic sites are the lungs, brain, and bones. Despite its rarity, ASPS is of high research interest due to its unique molecular pathogenesis and resistance to conventional chemotherapy.

ASPS is an ideal model for studying gene fusion-driven oncogenesis. The hallmark ASPSCR1-TFE3 fusion is present in over 90% of cases, providing a clear genetic driver. This fusion is amenable to CRISPR-based modeling, allowing researchers to introduce the translocation into isogenic cell lines to study its functional consequences. Public datasets, such as those from TCGA (though limited due to rarity) and the COSMIC database, provide mutation and expression data. Open questions include the role of the fusion in transcriptional reprogramming, the tumor microenvironment, and resistance to anti-angiogenic therapies. Gene-edited models are essential to dissect these mechanisms.

The primary oncogenic driver in ASPS is the ASPSCR1-TFE3 fusion protein, which acts as an aberrant transcription factor. Key pathways include:

• • TFE3-mediated transcriptional activation: The fusion protein retains the DNA-binding domain of TFE3, leading to overexpression of downstream targets.
• • MET signaling: TFE3 directly upregulates MET, activating the HGF/MET axis, promoting proliferation and invasion.
• • HIF1A pathway: The fusion stabilizes HIF1A, leading to a pseudo-hypoxic state and upregulation of VEGF, contributing to angiogenesis.
• • PI3K/AKT/mTOR: Constitutive activation of this pathway supports cell survival and growth.

Data from COSMIC (v100) and TCGA (SARC cohort, limited ASPS cases).

The ASPSCR1-TFE3 fusion deregulates multiple signaling networks:

• • MET/HGF axis: Upregulation of MET leads to activation of downstream MAPK and PI3K pathways.
• • HIF1A/VEGF axis: Pseudo-hypoxic conditions promote angiogenesis.
• • PI3K/AKT/mTOR: Constitutive activation supports cell growth and survival.
• • Wnt/β-catenin: Crosstalk with TFE3 may enhance proliferation.

Key nodes for targeted intervention include MET, VEGFR, and mTOR.

Organoid models of ASPS are emerging, offering 3D culture systems that better recapitulate the tumor microenvironment. However, they are not yet widely available. Gene-edited cell lines, such as those with the ASPSCR1-TFE3 fusion introduced via CRISPR, are valuable for mechanistic studies.

• • Patient-derived xenografts (PDX): Established by implanting ASPS tumor fragments into immunodeficient mice. These models retain the original tumor's genetic and histological features.
• • Genetically engineered mouse models (GEMM): Conditional expression of ASPSCR1-TFE3 in mesenchymal stem cells has been attempted, but no fully penetrant GEMM exists yet.
• • Cell line-derived xenografts: Using ASPS cell lines injected subcutaneously or orthotopically.
• • Induced models: CRISPR-engineered human cell lines with the fusion can be used in xenograft studies.

CRISPR-based gene editing enables the creation of isogenic cell lines with precise genetic modifications. For ASPS, researchers can:

• • Knock-in the ASPSCR1-TFE3 fusion into a non-transformed cell line (e.g., HEK293 or mesenchymal stem cells) to study its oncogenic effects.
• • Knockout TFE3 in ASPS cell lines to validate its dependency.
• • Introduce point mutations in genes like MET or PTEN to study resistance mechanisms.

Commercially available, sequence-verified gene-edited models accelerate research by providing consistent and validated tools. These models are essential for drug screening and functional genomics.

Gene-edited cell lines are used to validate the role of specific genes in ASPS. For example:

• • TFE3 knockout in ASPS cell lines reduces proliferation and invasion, confirming its oncogenic role.
• • ASPSCR1-TFE3 knock-in in non-transformed cells induces transformation, providing a model to study early events.
• • MET knockout or knockdown can assess the dependency on MET signaling.

Isogenic pairs (e.g., wild-type vs. TFE3 knockout) are used in high-throughput screens to identify compounds that selectively target ASPS cells. Resistance models can be generated by chronic exposure to drugs like crizotinib (MET inhibitor) or sunitinib (VEGFR inhibitor), followed by CRISPR editing to identify resistance mutations.

CRISPR-based synthetic lethality screens can identify genes that, when knocked out, are lethal only in ASPS cells. This approach can uncover novel therapeutic targets and biomarkers. For example, screening for vulnerabilities in the MET pathway or DNA repair pathways.